Neoprobe gets OK for Lymphoseek study

By staff writers

April 16, 2008 -- Gamma camera probe developer Neoprobe has received U.S. Food and Drug Administration clearance to launch a phase III multicenter clinical study of its Lymphoseek radiopharmaceutical agent.

The Dublin, OH-based firm plans to enroll approximately 200 patients at up to 25 cancer treatment centers in the U.S. and Europe. Neoprobe said that it is also preparing for a second phase III trial to involve fewer than 200 patients with head and neck squamous cell carcinoma. That trial is expected to begin around midyear, according to the firm.

In other news, the company has received $3 million in funding from investment fund Platinum-Montaur Life Sciences of New York City, Neoprobe said. The funds will be used to begin the phase III clinical trials of Lymphoseek.

Neoprobe announces phase II Lymphoseek results, March 13, 2008

Neoprobe nets financing, December 27, 2007

Neoprobe extends agreement with Ethicon, December 20, 2007

Neoprobe, Cardinal Health ink distribution deal, November 28, 2007

Neoprobe cuts loss on higher sales, October 31, 2007

Copyright © 2008


To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking